



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Editorial Office
✉ research.integrity@frontiersin.org

RECEIVED 07 February 2024
ACCEPTED 10 February 2024
PUBLISHED 22 February 2024

CITATION
Frontiers Editorial Office (2024) Retraction: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma. *Front. Oncol.* 14:1383375. doi: 10.3389/fonc.2024.1383375

COPYRIGHT
© 2024 Frontiers Editorial Office. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Retraction: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma

Frontiers Editorial Office*

A Retraction of the Original Research Article

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma

by Yang Q, Li G, Wu X, Lin H, Wu W, Xie X, Zhu Y, Cai W, Shi C and Zhuo S (2023) *Front. Oncol.* 13:1136366. doi: 10.3389/fonc.2023.1136366

The journal retracts the 2023 article cited above.

Following publication, the publisher identified concerns regarding the scope and peer review of this article. A subsequent investigation, which was conducted in accordance with Frontiers' policies, found indicators of third-party involvement and inadequate peer review process. As the scientific integrity of the article cannot be guaranteed, and adhering to the recommendations of the Committee on Publication Ethics (COPE), the article is retracted.

The authors have not responded to this retraction.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers.